Physician profile
Alan Kuo
NPI 1699193391
$984.90
in general payments reported to CMS, 2019-2025
9 companies · $15.09 in 2025
The $15.09 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.23 · 2020: $19.83 · 2021: $324 · 2022: $238 · 2023: $163 · 2024: $176 · 2025: $15.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $305.66 | 2019-2024 | |
| Abiomed | $261.22 | 2022-2024 | Impella |
| Lantheus Medical Imaging, INC. | $138.19 | 2019-2024 | Definity |
| E.R. Squibb & Sons, L.L.C. | $121.61 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.53 | 2021-2022 | |
| Amarin Pharma, INC. | $55.54 | 2021 | |
| Allergan, INC. | $19.83 | 2020 | |
| Amgen INC. | $15.09 | 2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $3.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.